Reservoir, a venture from the team behind Cellino, now offers adults cryopreservation of their own peripheral blood mononuclear cells — roughly five vials of five million cells each, collected via a standard 60-milliliter blood draw and stored below −150°C. The underlying premise is that immune cells accumulate age-related changes, including loss of naive T cells and expansion of mutated clones, so earlier samples may be more useful starting material. Whether banked cells of this quantity can serve future autologous therapies remains undetermined, as current CAR-T manufacturing typically relies on far larger apheresis collections.
Key Points
- Standard blood draw banks five vials of mononuclear cells indefinitely
- Naive T cells decline and mutated clones expand with age
- No defined therapeutic application; cord blood banking offers cautionary precedent
Longevity Analysis
Immune aging is measurable well before it becomes clinically apparent — declining naive T cell reserves and clonal expansion in the blood track with infection susceptibility, cancer surveillance failure and vaccine response. Preserving younger cells is a wager that future manufacturing capability will make the starting material worth more than the storage cost, a question that depends on expansion and reprogramming methods not yet mature. The more immediately actionable interpretation is that immune cell quality is a time-sensitive asset, which places weight on reducing the chronic inflammatory and metabolic burden that accelerates its decline rather than on storing a sample against it.
Original published by Longevity.Technology, by Eleanor Garth.